SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany, Unitiv Blog, RealWire News Distribution, Jason Bloomberg

News Feed Item

Frost & Sullivan Applauds Ostendum's Development of Multiplexing, Disposable Chips for the Lab-on-Chips Nanodevices Market

-- The group is focused on developing sensitive biosensors, and less expensive optical systems, with the aim of improving the performance of LOC devices

LONDON, Jan. 7, 2014 /PRNewswire/ -- Based on its recent analysis of the Lab-on-a-Chip (LOC) nanodevices market, Frost & Sullivan recognizes Ostendum R&D BV (Ostendum) with the 2013 European Frost & Sullivan Award for Technology Innovation Leadership. Ostendum is a group of companies focused on the development and production of fast, highly sensitive, portable, easy-to-use and cost-effective biosensors for the instantaneous detection of micro-organisms and biomolecules, including biomarkers, proteins and nucleic acids. The group has successfully created proprietary LOC nanodevices, based on an integral optical technology platform developed by Aurel Ymeti, who is the co-founder and CTO of Ostendum, during his doctoral research that was previously highlighted in Technical Insights of Frost & Sullivan. Ostendum's LOC nanodevices have detection limits that are at least 100 times deeper than currently available LOC devices.

Click here for the full multimedia experience of this release - http://bit.ly/19YNxTs

Ostendum's chip has at least four independent sensing channels, one of which is used as the reference channel, while the other three constitute the measurement channels. As the latter three can be used to perform the simultaneous detection of three different analytes, it confers the device multiplexing capabilities. Using Ostendum's technology, one can analyze most complex samples such as full blood or whole milk.

The company has constructed a novel method of measurement, wherein one analyte or class of analytes is detected selectively. It involves the pre-coating of each measurement channel with a unique receptor layer. The receptor, typically an antibody, can specifically bind to one class of micro-organisms or biomolecules, whereas the antigen is specifically bound at the measurement channel. This feature distinguishes the product, enabling the user to pre-coat the LOC system with the desired receptors or use pre-coated disposable LOC systems provided by Ostendum.

"By confining the samples containing the test fluid to the microfluidic inlet of the LOC system, the device offers continuous flow, enabling the monitoring of samples in-line and in real time," said Frost & Sullivan Senior Research Analyst Cecilia Van Cauwenberghe. "It guarantees continuous flow and homogeneity by means of a micro-pump located in such a way that the channels are specifically addressed on the chip."

In addition to multiple applications in human healthcare, Ostendum's technology platform is applied in veterinary and plant health, food and beverage, environment and security monitoring. Similarly, LOC devices can be utilized for onsite drinking and waste water analysis, untreated (raw) milk, beverages and food sampling, among many others.

Ostendum's LOC nanodevice will find wide application in early disease diagnostics, especially for cancer and heart diseases. Some of its future applications could include food analysis, e.g. species-specific (Halal) tests, safety, environmental monitoring and R&D pharma.

Ostendum is currently speeding up the development of its LOC system to be pre-packed and pre-coated as a low-cost disposable. In the context of this development, Ostendum is preparing to increase its device multiplexing capabilities to aid the simultaneous detection of up to ten different analytes in a single sample.

Frost & Sullivan finds that being an industrial partner with the University Twente, the Research Institute for Nanotechnology, MESA+, and the High Tech Factory initiative, Ostendum is positioned as an innovator leader in Europe. As evidence of its commitment to extend its technology's application to diverse markets, Ostendum has applied for a portfolio of selected patents.

"However, beyond all its superior features, it is the technology's portability, easy-handling, light weighting and minimal power requirement that make it suitable for a broad spectrum of applications and industries," noted Van Cauwenberghe.

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing a technology, which significantly impacts both the functionality and the customer value of new products and applications. The award lauds the relevance of the innovation to the industry.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research to identify best practices in the industry.

About Ostendum

Ostendum is a group of companies that commercializes Lab-on-a-Chip optical biosensing nanodevices for detection of micro-organisms, biomarkers, (bio-) molecules and nano-particles. Ostendum develops and produces both the necessary hardware and software, including its own Lab-on-a-Chip system. Ostendum's Lab-on-a-Chip interferometric nanotechnology is unique, being completely label-free, instantaneous - analysis is performed literally within minutes - and extremely sensitive, being at least 100 times more sensitive than all currently available competing detection methods. This has enabled, among others, detection of various bacteria in whole milk, numerous viruses in (human/patient) serum and many biomarkers in plasma and full blood without time-consuming pre-concentration handling, contributing to faster analysis and savings on operational costs.

Ostendum's technology, which is qualified by Forbes as one of the "13 Amazing New Nanotechnologies", is versatile and broadly applicable in areas such as human healthcare for (early) disease diagnosis and as a tool for personalized medicine at point-of-care, veterinary and plant health, food and beverage safety, drinking/waste water monitoring, biological warfare and R&D markets.

Ostendum raised venture capital from the public-private incubator fund UT International Ventures and from Achmea, the largest health insurer of the Netherlands.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation

Contact:

Emily Bailey
Best Practices
P: +44(0)20-7915-7869
[email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.